Bipolar Disorder Trial, Recruiting NCT06740383 Sponsor: Beth Israel Deaconess Medical Center Condition: Bipolar Disorder
Back to Bipolar Disorder

Bipolar Disorder Trial, Recruiting

NCT06740383
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a male or female of any race or ethnicity
  • You are between 18 and 40 years old
  • You have been diagnosed with a psychotic disorder, such as schizophrenia, schizoaffective disorder, bipolar I disorder with psychotic features, major depression with psychotic features, delusional disorder, or a similar condition
  • You are able to read, speak, and understand English
  • You are willing and able to sign a consent form and follow the study's requirements
  • Your psychosis symptoms began 4 years ago or less
  • At the start of the study, you are already receiving both medication and therapy for your condition

Who may not be able to join:

  • You have a low estimated pre-illness intellectual ability based on a specific reading test (confirm with trial site)
  • You have a neurological or medical condition that may affect how your brain works, such as epilepsy, a serious brain injury involving 30 or more minutes of unconsciousness, a history of stroke, or AIDS
  • Your psychosis appears to be caused by alcohol or drug use — though people with cannabis use unrelated to their psychosis may still be eligible (confirm with trial site)
  • You are pregnant
  • You have metal objects inside your body that are magnetic, which could be unsafe in an MRI scanner
  • You weigh more than 300 lbs or your body size exceeds what the MRI scanner can accommodate
  • You experience severe anxiety in enclosed spaces (claustrophobia)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matcheri S. Keshavan, MD, Beth Israel Deaconess Medical Center

Phone: 617-754-1256

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 January 2023
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Treatment Response; Symptomatic Remission; Functional Remission; Relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov